Improved Survival Rates Among Acute Myeloid Leukemia (AML) Patients 65 to 74 Years: Population-Based Estimates Over Three Decades,Mya S TheinAhmedin JemalMaria R. BaerWilliam B ErshlerJerome W Yates
"After adjusting for other factors, rates of change in risk of leukemia-related death were greater for younger than older patients with ALL or AML, but were not significantly influenced by socio-economic status or remoteness." Beckmann and colleagues suggested several factors may have contributed to...
Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. The main difference between the two cooperative studies on therapy of childhood acute myelogenous leukemia AML-BFM-78 ...
For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the February issue ofLeukemia Research. Hannah Goulart, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and...
Acute myeloid leukemia Relapse Allogeneic transplantation Donor lymphocyte infusion Second transplantation Introduction Allogeneic hematopoietic cell transplantation (alloHCT) is a potentially curative treatment option for patients with acute myeloid leukemia (AML); however, relapse accounts for approximately 40%...
The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature Twenty years of published literature was reviewed for chemotherapy regimens used to treat patients with acute myeloid leukemia (AML) in first relapse. Thir... Leopold,Lance,H.,... - 《Leukemia & ...
Human T-cell leukemia virus type 1 (HTLV-1) is a virus that causes a rare type of leukemia. Certain chemotherapydrugsfor cancer can increase the risk for AML or ALL. Age over 65 as well as being a make are risk factors for leukemia. ...
Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient’s organ functions. A type of anti-tumor immunotherapy called allogeneic hematopoi...
for cancer: The prospective multicenter SPOG 2015 FN Definition StudyEmergency management of fever and neutropenia in children with cancer: A reviewDe novo adult acute myeloid leukemia with two new mutations in juxtatransmembrane domain of the FLT3 gene: a case reportCytomegalovirus reactivation in ...
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.